Related references
Note: Only part of the references are listed.Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia
[Anonymous]
BLOOD (2013)
Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia
Emmanuelle Bouvet et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2013)
Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
A. C. Rawstron et al.
LEUKEMIA (2013)
Chronic myeloid leukemia: 2012 Update on diagnosis, monitoring, and management
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Early-onset Therapy-related Myelodysplastic Syndrome Originating from Prolonged Myelosuppression after Fludarabine-based Therapy
Sho Yamazaki et al.
INTERNAL MEDICINE (2012)
Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
Sebastian Boettcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
Eric Van Den Neste et al.
LEUKEMIA & LYMPHOMA (2012)
Treatment of Older Patients with Chronic Lymphocytic Leukemia
Nicole Lamanna
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2012)
Should Minimal Residual Disease Monitoring in Acute Lymphoblastic Leukemia be Standard of Care?
Dario Campana
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2012)
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
Xavier C. Badoux et al.
BLOOD (2011)
Is MRD eradication a desirable goal in CLL?
Carol Moreno et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
Assessment of minimal residual disease in acute myeloid leukemia
David Grimwade et al.
CURRENT OPINION IN ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Relevance of the Immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens
Katherine I. Lin et al.
BLOOD (2009)
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis
S. Boettcher et al.
LEUKEMIA (2009)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
W Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
P Moreton et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
